Company Profile
Pulmonx Stock Price, News & Analysis
- Ticker:
- LUNG
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
2.05 USD (+3.54%)
Close
Last updated: August 6, 2026
68M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, LUNG closed up 3.54% at $2.05. No new same-company headline was identified in the current news window.
Company overview
Minimally Invasive COPD Treatment
Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy.
Zephyr Endobronchial Valve
The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung regions, allowing healthier areas to function more effectively. It has FDA premarket approval, is available in more than 25 countries and is incorporated into treatment guidelines.
Patient Selection Tools
The Chartis Pulmonary Assessment System evaluates collateral ventilation to help determine whether a patient is suitable for valve therapy. StratX reports use CT imaging to characterize emphysema distribution and fissure completeness.
Digital Care Support
The LungTraX platform supports patient identification, referral and treatment workflow. Together with Zephyr, Chartis and StratX, it gives Pulmonx an integrated model spanning screening, procedural planning and therapy.
Future catalysts
Pulmonx’s next three months are about Zephyr Valve adoption, new physician-site expansion, and continued lung-volume-reduction procedure growth. The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
Recent news
- 01
Pulmonx Reports Second Quarter 2026 Financial Results
Source: Pulmonx
- 02
- 03
- 04
- 05
Pulmonx Reports First Quarter 2026 Financial Results
Source: Pulmonx
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pulmonx (LUNG)?
Pulmonx (LUNG) most recently closed at 2.05 USD, a +3.54% move versus the previous session.
What is the market cap of Pulmonx (LUNG)?
Pulmonx currently has a market capitalization of 68M USD on BioPharmSignal.
What does Pulmonx do?
Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung regions, allowing...
On which exchange is LUNG stock listed?
Pulmonx (LUNG) is associated with NASDAQ, United States, MedTech.
What is Minimally?
The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
Which conditions is Pulmonx targeting with Minimally?
The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
How does Pulmonx describe recent progress with Minimally?
The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
What is Invasive?
Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy.